Piramal Ent arm to acquire office space in Mumbai; stock surges
Piramal Enterprises says it will also keep aside funds to cover exposure to AIFs
Piramal Enterprises says it will also keep aside funds to cover exposure to AIFs
The product is anticipated to be launched in December 2023, the approved product is estimated to target a market size of $25.4 million.
The homegrown pharma company has outperformed the BSE Sensex and Healthcare index in terms of returns in the last one year.
Warning letter stresses data integrity issues at company embedded with product complaints and microbial contamination
The newly listed pharma company reported 52% growth in profit at ₹294 crore, while revenue from operations rose 19% to ₹2,053 crore in Q4FY23.
The IPO of the country’s fourth largest pharma company by domestic sales comprises an offer for the sale of 4 crore equity shares by the promoters and existing investors.
Dolo-650 manufacturer struck gold during the pandemic; was raided by IT in July, accusing it of bribing doctors through ₹1,000 crore “freebies” to push drug sale during the pandemic